Novel Serum Biomarkers Associated With Pediatric Hepatic Encephalopathy: A Systematic Review.
Journal
Journal of pediatric gastroenterology and nutrition
ISSN: 1536-4801
Titre abrégé: J Pediatr Gastroenterol Nutr
Pays: United States
ID NLM: 8211545
Informations de publication
Date de publication:
01 07 2023
01 07 2023
Historique:
medline:
19
6
2023
pubmed:
21
4
2023
entrez:
21
04
2023
Statut:
ppublish
Résumé
The pathophysiology of pediatric hepatic encephalopathy (HE) is not well understood. Various serum biomarkers associated with HE may provide insight into its pathology, but their use and interpretation in clinical practice for diagnosis and prognostication remain undetermined. We sought to investigate reported correlations of serum biomarkers with presence and degree of HE in children. We conducted a systematic review of studies examining novel serum biomarkers and cytokines in association with HE that included children on PubMed, Embase, Lilacs, and Scopus. We utilized Covidence for abstract and text review by 2 independent reviewers for each study. We reviewed 2824 unique publications; 15 met criteria for inclusion. Categories of biomarkers reported were inflammatory cytokines, products of amino acid metabolism, trace elements and vitamins, and hepatic and neuro biomarkers. Of 19 individual biomarkers, only 5 were measured in more than 1 study. Elevations in interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) were most commonly reported as associated with HE. Notably, we observed lower average IL-6 and TNF-alpha levels in pediatric-only studies compared to mixed age studies. Overall, high bias and poor applicability to our review question was observed. We encountered low numbers of studies with pediatric focus, and few conducted with low bias study designs. Investigated biomarkers span a large range of categories and suggest potentially useful correlations with HE. Further well-designed prospective biomarker research is necessary to better elucidate the pathogenesis of HE in children and improve early detection and clinical care.
Sections du résumé
BACKGROUND
The pathophysiology of pediatric hepatic encephalopathy (HE) is not well understood. Various serum biomarkers associated with HE may provide insight into its pathology, but their use and interpretation in clinical practice for diagnosis and prognostication remain undetermined. We sought to investigate reported correlations of serum biomarkers with presence and degree of HE in children.
METHODS
We conducted a systematic review of studies examining novel serum biomarkers and cytokines in association with HE that included children on PubMed, Embase, Lilacs, and Scopus. We utilized Covidence for abstract and text review by 2 independent reviewers for each study.
RESULTS
We reviewed 2824 unique publications; 15 met criteria for inclusion. Categories of biomarkers reported were inflammatory cytokines, products of amino acid metabolism, trace elements and vitamins, and hepatic and neuro biomarkers. Of 19 individual biomarkers, only 5 were measured in more than 1 study. Elevations in interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) were most commonly reported as associated with HE. Notably, we observed lower average IL-6 and TNF-alpha levels in pediatric-only studies compared to mixed age studies. Overall, high bias and poor applicability to our review question was observed. We encountered low numbers of studies with pediatric focus, and few conducted with low bias study designs.
CONCLUSION
Investigated biomarkers span a large range of categories and suggest potentially useful correlations with HE. Further well-designed prospective biomarker research is necessary to better elucidate the pathogenesis of HE in children and improve early detection and clinical care.
Identifiants
pubmed: 37084331
doi: 10.1097/MPG.0000000000003801
pii: 00005176-202307000-00003
doi:
Substances chimiques
Tumor Necrosis Factor-alpha
0
Interleukin-6
0
Biomarkers
0
Cytokines
0
Types de publication
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
16-23Informations de copyright
Copyright © 2023 by European Society for European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest.
Références
Luo M, Li L, Yang EN, et al. Correlation between interleukin-6 and ammonia in patients with overt hepatic encephalopathy due to cirrhosis. Clin Res Hepatol Gastroenterol. 2013;37:384–90.
Foerster BR, Conklin LS, Petrou M, et al. Minimal hepatic encephalopathy in children: evaluation with proton MR spectroscopy. AJNR Am J Neuroradiol. 2009;30:1610–3.
D’Antiga L, Dacchille P, Boniver C, et al. Clues for minimal hepatic encephalopathy in children with noncirrhotic portal hypertension. J Pediatr Gastroenterol Nutr. 2014;59:689–94.
Dara N, Sayyari AA, Imanzadeh F. Hepatic encephalopathy: early diagnosis in pediatric patients with cirrhosis. Iran J Child Neurol. 2014;8:1–11.
Schölmerich J, Holstege A. Aetiology and pathophysiology of chronic liver disorders. Drugs. 1990;40:3–22.
Cochran JB, Losek JD. Acute liver failure in children. Pediatr Emerg Care. 2007;23:129–35.
Ciećko-Michalska I, Szczepanek M, Słowik A, et al. Pathogenesis of hepatic encephalopathy. Gastroenterol Res Pract. 2012;2012:642108.
Ong JP, Aggarwal A, Krieger D, et al. Correlation between ammonia levels and the severity of hepatic encephalopathy. Am J Med. 2003;114:188–93.
Aldridge DR, Tranah EJ, Shawcross DL. Pathogenesis of hepatic encephalopathy: role of ammonia and systemic inflammation. J Clin Exp Hepatol. 2015;5:S7–S20.
Jayakumar AR, Norenberg MD. Hyperammonemia in hepatic encephalopathy. J Clin Exp Hepatol. 2018;8:272–80.
Gonzalez JJ, Tapper EB. A prospective, blinded assessment of ammonia testing demonstrates low utility among front-line clinicians. Clin Gastroenterol Hepatol. 2022;20:e895–6.
Bajaj JS, Bloom PP, Chung RT, et al. Variability and lability of ammonia levels in healthy volunteers and patients with cirrhosis: implications for trial design and clinical practice. Am J Gastroenterol. 2020;115:783–5.
Machado MV. Liquid diagnosis of hepatic encephalopathy: are we there already? GE Port J Gastroenterol. 2020;27:378–82.
Norenberg MD, Jayakumar AR, Rao KVR, et al. New concepts in the mechanism of ammonia-induced astrocyte swelling. Metab Brain Dis. 2007;22:219–34.
Milewski K, Oria M. What we know: the inflammatory basis of hepatic encephalopathy. Metab Brain Dis. 2016;31:1239–47.
Onal IK, Akdogan M, Oztas E, et al. Does interleukin-18 play a role in the pathogenesis of hepatic encephalopathy? Hepatogastroenterology. 2011;58:497–502.
Flisiak R, Pytel-Krolczuk B, Prokopowicz D. Circulating transforming growth factor β1 as an indicator of hepatic function impairment in liver cirrhosis. Cytokine. 2000;12:677–81.
Wigmore SJ, Walsh TS, Lee A, et al. Pro-inflammatory cytokine release and mediation of the acute phase protein response in fulminant hepatic failure. Intensive Care Med. 1998;24:224–9.
Wiltfang J, Nolte W, Otto M, et al. Elevated serum levels of astroglial S100β in patients with liver cirrhosis indicate early and subclinical portal-systemic encephalopathy. Metab Brain Dis. 1999;14:239–51.
Tsai CF, Chu CJ, Huang YH, et al. Detecting minimal hepatic encephalopathy in an endemic country for hepatitis B: the role of psychometrics and serum IL-6. PLoS One. 2015;10:e0128437.
Papadopoulos N, Soultati A, Goritsas C, et al. Nitric oxide, ammonia, and CRP levels in cirrhotic patients with hepatic encephalopathy: Is there a connection? J Clin Gastroenterol. 2010;44:713–9.
Montoliu C, Piedrafita B, Serra MA, et al. IL-6 and IL-18 in blood may discriminate cirrhotic patients with and without minimal hepatic encephalopathy. J Clin Gastroenterol. 2009;43:272–9.
Yang YY. Can serum cytokines predict hepatic cytokine expression in liver cirrhosis? J Chin Med Assoc. 2011;74:485–6.
Odeh M, Sabo E, Srugo I, Oliven A. Serum levels of tumor necrosis factor-α correlate with severity of hepatic encephalopathy due to chronic liver failure. Liver Int. 2004;24:110–6.
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
Toney NA, Bell MJ, Belle SH, et al. Hepatic encephalopathy in children with acute liver failure: utility of serum neuromarkers. J Pediatr Gastroenterol Nutr. 2019;69:108–15.
Jain L, Sharma BC, Srivastava S, et al. Serum endotoxin, inflammatory mediators, and magnetic resonance spectroscopy before and after treatment in patients with minimal hepatic encephalopathy. J Gastroenterol Hepatol. 2013;28:1187–93.
Srivastava A, Yadav SK, Borkar VV, et al. Serial evaluation of children with ALF with advanced MRI, serum proinflammatory cytokines, thiamine, and cognition assessment. J Pediatr Gastroenterol Nutr. 2012;55:580–6.
Dhatt PS, Gupta HL, Saini AS. Blood and urinary ketoacids in Indian childhood cirrhosis. Indian J Pediatr. 1967;34:238–41.
Izumi S, Hughes RD, Langley PG, Pernambuco JR, Williams R. Extent of the acute phase response in fulminant hepatic failure. Gut. 1994;35:982–6.
Gupta RK, Yadav SK, Rangan M, et al. Serum proinflammatory cytokines correlate with diffusion tensor imaging derived metrics and 1 H-MR spectroscopy in patients with acute liver failure. Metab Brain Dis. 2010;25:355–61.
Dhatt PS, Singh H, Gupta HL. Glutamine studies in Indian childhood cirrhosis. Indian J Med Res. 1974;62:454–9.
Watanabe A, Hayashi S, Higashi T, et al. Characteristic change in serum amino acid levels in different types of hepatic encephalopathy. Gastroenterol Jpn. 1982;17:218–23.
Wyke RJ, Yousif-Kadaru AG, Rajkovic IA, Eddleston AL, Williams R. Serum stimulatory activity and polymorphonuclear leucocyte movement in patients with fulminant hepatic failure. Clin Exp Immunol. 1982;50:442–9.
Srivastava A, Chaturvedi S, Gupta RK, et al. Minimal hepatic encephalopathy in children with chronic liver disease: prevalence, pathogenesis and magnetic resonance-based diagnosis. J Hepatol. 2017;66:528–36.
Manghani KK, Lunzer MR, Billing BH, Sherlock S. Urinary and serum octopamine in patients with portal-systemic encephalopathy. Lancet. 1975;306:943–6.
Srivastava A, Yadav SK, Yachha SK, et al. Pro-inflammatory cytokines are raised in extrahepatic portal venous obstruction, with minimal hepatic encephalopathy. J Gastroenterol Hepatol. 2011;26:979–86.
Singh V, Bhattacharya SK, Sundar S, Kachhawaha JS. Zinc levels in the cerebrospinal fluid, serum & urine in acute hepatic encephalopathy. Indian J Med Res. 1988;87:594–9.
Jain L, Sharma BC, Sharma P, et al. Serum endotoxin and inflammatory mediators in patients with cirrhosis and hepatic encephalopathy. Dig Liver Dis. 2012;44:1027–31.
Minuk GY, Sarjeant EJ, Buchan K. Elevated serum gamma-aminobutyric acid levels in children with Reye’s syndrome. J Pediatr Gastroenterol Nutr. 1985;4:528–31.
Whiting PF, Rutjes AWS, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529–36.
Hercz A. The inhibition of proteinases by human α1‐antitrypsin. Eur J Biochem. 1974;49:287–92.
Dunlea DM, Fee LT, McEnery T, McElvaney NG, Reeves EP. The impact of alpha-1 antitrypsin augmentation therapy on neutrophil-driven respiratory disease in deficient individuals. J Inflamm Res. 2018;11:123–34.
Perlmutter DH. Alpha-1-antitrypsin deficiency: diagnosis and treatment. Clin Liver Dis. 2004;8:839–59, viii.
Brown GC. The endotoxin hypothesis of neurodegeneration. J Neuroinflammation. 2019;16:180.
Kabiraj P, Valenzuela CA, Marin JE, et al. The neuroprotective role of Ferrostatin-1 under rotenone-induced oxidative stress in dopaminergic neuroblastoma cells. Protein J. 2015;34:349–58.
Ng VL, Li R, Loomes KM, et al. Outcomes of children with and without hepatic encephalopathy from the pediatric acute liver failure study group. J Pediatr Gastroenterol Nutr. 2016;63:357–64.
Khan A, Ayub M, Khan WM. Hyperammonemia is associated with increasing severity of both liver cirrhosis and hepatic encephalopathy. Int J Hepatol. 2016;2016:1–5.
Noiret L, Baigent S, Jalan R. Arterial ammonia levels in cirrhosis are determined by systemic and hepatic hemodynamics, and by organ function: a quantitative modelling study. Liver Int. 2014;34:e45–55.
Lee WS, McKiernan P, Kelly DA. Etiology, outcome and prognostic indicators of childhood fulminant hepatic failure in the United Kingdom. J Pediatr Gastroenterol Nutr. 2005;40:575–81.
Debray D, Cullufi P, Devictor D, Fabre M, Bernard O. Liver failure in children with hepatitis A. Hepatology. 1997;26:1018–22.